Wilson’s Disease Drugs Market

Market Insights

Wilson’s disease occurs equally in both male and female populations, but research studies have cited differences in the sex-specific phenotypes. Hepatic symptoms occur 55%–60% more often in the female population. Frank psychosis is more prevalent in the male population and is often mistaken for bipolar disorder or schizophrenia. In the near future, gene therapy can be used to transfer the ATPB7 gene if sufficient amounts of the transgene are expressed in the liver cells for a longer period of time. It is very important for the accurate diagnosis of Wilson’s disease, which could have fatal consequences if not done appropriately.

The early diagnosis of Wilson’s disease is primarily based on multiple indications, such as hepatic, neuropsychiatric, ophthalmic, and others. The chelators are the first line of therapy, which includes penicillamine and trientine. Zinc acetate is considered the only mineral prescribed for patients who are resistant to chelator therapy. Data mining and market estimation are covered in the scope of the report to understand the opportunity for novel drug discovery in the treatment of Wilson’s disease.

Market estimation and data mining are helpful in understanding the current treatment regimen and regulatory norms prevalent in different geographical regions.

An attractive investment proposition gives a genuine understanding of the disease prevalence in different countries through data mining and the approach adopted to consider the treatment regimen for Wilson’s disease. The product portfolio gives an idea of the different dietary supplements enriched in zinc primarily used for the management of Wilson’s disease. Recent news coverage sheds light on the strategic collaboration taking place in the healthcare sector to launch novel drug discovery for the treatment of Wilson’s disease. The manufacturers that are active in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc., and Wilson Therapeutics AB.

Based on indications, the global Wilson’s disease drugs market is categorized into

• Hepatic
• Neuropsychiatric
• Ophthalmic
• Others (heart and kidney complications)

Wilson’s disease is a rare hereditary disorder that occurs due to the accumulation of copper in different body organs such as the liver, brain, eyes, and other vital organs. The disease takes place due to a mutation in the ATP7B gene. The prevalence rate of Wilson’s disease is 1 in 30,000 persons; it is usually diagnosed in the young and adult age groups. Hepatic indications are first diagnosed in the disease manifestation of Wilson’s disease on account of reduced biliary excretion of copper, which results in excessive accumulation of copper in the liver. The early symptoms manifested in liver indications are tiredness and hepatitis with elevated levels of gamma-glutamyl transpeptidase, alanine aminotransferase, and aspartate aminotransferase. The neuropsychiatric symptoms manifest in the later stages of the disease’s manifestation, with the basal ganglia hampering coordinated movement.

The major symptoms are Parkinsonism, tremors, ataxia, dystonia, and seizures. In approximately 90 percent of the patients exhibiting neuropsychiatric symptoms, the development of Kayser-Fleisher rings (deposition of copper) in the corneal region of the eyes is evident. The manufacturers that are active in the treatment of Wilson’s disease are Kadmon Holdings, Inc., Merck & Co., Noble Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Tsumura & Co., Valeant Pharmaceuticals International, Inc., VHB Life Sciences, Inc., and Wilson Therapeutics AB.

Based on drug class, Wilson’s disease drug market is categorized into:

Chelators

• Penicillamine
• Trientine

Minerals

• Zinc Acetate

The primary diagnosis of Wilson’s disease is complicated, as the symptoms are similar to those of other diseases, such as hepatitis C, seizures, jaundice, heavy metal poisoning, and cerebral palsy. Despite the fact that Wilson’s disease is a hereditary genetic disease, a person is unlikely to acquire the ATPB7 mutation if only one abnormal gene is inherited from either parent. The management of the disease is entirely focused on compensating for the abnormal copper metabolism.

As if chelators are now the first line of treatment for Wilson’s disease patients seeking symptomatic relief, Chelators deplete the excessive copper levels in the body by expediting their excretion through urine but being nonspecific to copper, they also bind and excrete other micronutrients from the body. The adverse effects related to chelators are severe, such as bone marrow suppression and kidney complications, thereby hampering their market growth. Zinc acetate is the only mineral recommended as an alternative therapy to chelators. It works by reducing the dietary uptake of copper in the gastrointestinal tract and excreting it through feces. Because its effects are extremely slow, it is only used for maintenance therapy.

For the purpose of this study, the global Wilson’s disease drugs market is categorized into the following regional and country-specific markets:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Russia
  • Rest of Europe
• Asia-Pacific
  • India
  • China
  • Japan
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

According to the U.S. Department of Health and Human Services 2015 countrywide survey, the prevalence of Wilson’s disease in the United States is 1 in 55,000 births, with an allele frequency rate of 0.00428. North America is the most significant market in Wilson’s disease treatment drugs market on account of the high Wilson’s disease heterozygote frequency rate of 0.855% in the Caucasian population. The autosomal recessive rate of Wilson’s disease is approximately 25% in Europe, with patients being resistant to chelator therapy and the E.U. approving only zinc acetate for Wilson’s disease management in Europe. Being an orphan disease, the European Medical Agency is proactively investing in novel drug discovery for Wilson’s disease. The neuropsychiatric indications related to Wilson’s disease are on the rise in Asia and the Pacific. The market is heavily dependent on treatment drugs imported from the U.S. and Europe, which creates a huge opportunity for the existing generic market in Asia-Pacific.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Wilson’s Disease Treatment Drugs Market Portraiture
2.1.1. Global Wilson’s Disease Treatment Drugs Market, by Indication, 2016 (Value %)
2.1.2. Global Wilson’s Disease Treatment Drugs Market, by Drug Class, 2016 (Value %)
2.1.3. Global Wilson’s Disease Treatment Drugs Market, by Geography, 2016 (Value %)

Chapter 3. Wilson’s Disease Treatment Drugs Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Wilson’s Disease Drugs Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape : Global Wilson’s Disease Drugs Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market, by Indication, 2016
4.3. Hepatic
4.4. Neuropsychiatric
4.5. Ophthalmic
4.6. Others (Heart and Kidney Complications)

Chapter 5. Global Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Wilson’s Disease Drugs Market, by Drug Class, 2016
5.2. Chelators
5.2.1. Penicillamine
5.2.2. Trientine
5.3. Minerals
5.3.1. Zinc Acetate
5.4. Pipeline Analysis
5.4.1. Phase III Drug
5.4.1.1. WTX101 (bis-choline tetrathiomolybdate)

Chapter 6. Global Wilson’s Disease Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.2.1. North America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.2.2. North America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.3. North America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.3.1. Europe Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.3.2. Europe Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.3. Europe Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of Asia Pacific
6.5. Latin America Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.5.1. Latin America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa Wilson’s Disease Drugs Market Analysis, 2015 – 2025
6.6.1. Middle East and Africa Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
6.6.2. Middle East and Africa Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.3. Middle East and Africa Wilson’s Disease Drugs Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East and Africa

Chapter 7. Company Profiles
7.1. Kadmon Holdings, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Merck & Co.
7.3. Noble Pharma Co., Ltd.
7.4. Teva Pharmaceutical Industries Limited
7.5. Tsumura & Co.
7.6. Valeant Pharmaceuticals International, Inc.
7.7. VHB Life Sciences, Inc.
7.8. Wilson’s Therapeutics AB

List of Figures

FIG. 1 Wilson’s Disease Drugs: Market Segmentation
FIG. 2 Global Wilson’s Disease Drugs Market Share, by Indication, 2016 (Value %)
FIG. 3 Global Wilson’s Disease Drugs Market Share, by Drug Class, 2016 (Value %)
FIG. 4 Global Wilson’s Disease Drugs Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Hepatic Indications Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 8 Global Neuropsychiatric Indications Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 9 Global Ophthalmic Indications for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 10 Global Other Indications Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 11 Global Penicillamine Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 12 Global Trientine Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 13 Global Zinc Acetate Market for Wilson’s Disease Drugs, 2015 – 2025 (US$ Mn)
FIG. 14 U.S. Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 15 Canada Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 16 U.K. Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 17 Germany Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Rest of Europe Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 Japan Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 China Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 India Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Asia Pacific Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 Brazil Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Mexico Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 Rest of Latin America Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 GCC Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Middle East and Africa Wilson’s Disease Drugs Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Wilson’s Disease Drugs Market Portraiture
TABLE 2 Global Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 3 Global Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 Global Chelators Market for Wilson’s Disease Drugs, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 Global Minerals Market for Wilson’s Disease Drugs, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Global Wilson’s Disease Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 7 North America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 8 North America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 North America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Europe Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 11 Europe Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 12 Europe Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Asia Pacific Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 14 Asia Pacific Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 15 Asia Pacific Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 16 Latin America Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 17 Latin America Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 18 Latin America Wilson’s Disease Drugs Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 19 Middle East and Africa Wilson’s Disease Drugs Market, by Indication, 2015 – 2025 (US$ Mn)
TABLE 20 Middle East and Africa Wilson’s Disease Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 21 Middle East and Africa Wilson’s Disease Drugs Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 22 Kadmon Holdings, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Noble Pharma Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Teva Pharmaceutical Industries Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Tsumura & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 VHB Life Sciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Wilson Therapeutics AB: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)